Leading life sciences and other deep-tech venture investmentsManaging AVITIC Innovation Fund, focusing on Taiwanese deep-tech ecosystem

Leading life sciences investments

Led venture capital investment in life sciences and other areas• Focused on next-generation genomic and proteomic technologies• Identified companies of interest and conducted scientific/technical evaluation as well as financial analysis, site visits, and management team assessment• Managed portfolio companies by monitoring quarterly progress, offering strategic advice, and connecting the companies with prospective collaborators/investors• Liaised with life sciences venture funds invested to ensure effective collaboration • Closed semiconductor investment deals by driving term sheet finalization and internal/external coordination cross various functions Built comprehensive Proteomics Product Strategy with $500+ million projected annual revenue in 5 years• Analyzed competitive landscape and technology trends via primary and secondary market research • Identified unmet needs and product adoption criteria via literature review and customer engagement• Defined core and add-on technical capabilities based on learnings from academic conferences, key opinion leaders, customers, and companies• Recommended potential acquisition targets based on platform technology and potential synergies with semiconductor industry• Proposed high-level go-to-market strategy by recognizing beachhead and expansion applications for each customer segment

Strategy• Developed Biopharmaceutical strategy with targeting sales of $7-10 billion/yr for a top global pharmaceutical company by evaluating capability/capacity, analyzing competitive landscape, identifying business development targets, assessing company-specific technology platforms, and defining portfolio selection process• Identified indication expansion opportunities worth $500+ million NPV for a $20 million/yr product of a mid-sized global pharmaceutical company; built business cases through literature research, physician interviews, and market analyses• Conducted commercial diligence on an $300+ million/yr oncology asset for a mid-sized global pharmaceutical company through market research, expert interviews, and revenue/investment projections• Built action plans to expand market assess of a vaccine in two countries for a top global pharma company by synthesizing current state and defining objectives in ideation workshops with global/regional/country teams Operations• Developed post-merger CRO partnership and operating models for a top specialty pharmaceutical company through 50+ stakeholder interviews, industry benchmarking, and clinical trial spend analyses• Facilitated finalization and communication of post-merger R&D operating model for a top specialty pharmaceutical company, resulting in board approval and implementation of recommendations• Established comprehensive internal/external perspectives on sourcing decisions for end-to-end R&D activities by expert and stakeholder interviews at a top global pharmaceutical company to serve as the basis for the 10-year strategic review • Identified 30% overhead and 46% operating cost savings in IT, compliance, and supply chain functions for a United States subsidiary of a leading global pharmaceutical company; defined initiatives, implementation plans, and tracking mechanisms to drive significant saving realization

• Advised clients on biomedical research design, data analysis, and manuscript preparation• Bridged communication between clients and foreign editors

• Performed experiments, executed research projects, and managed lab administration

• Coordinated weekly executive board meetings• Designed and assisted record/policy presentation for biannual national hospital evaluation